Sernicola Alvise, Lampitelli Salvatore, Marraffa Federica, Maddalena Patrizia, Grassi Sara, Richetta Antonio Giovanni, Calvieri Stefano
Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy.
F1000Res. 2019 Jun 21;8:933. doi: 10.12688/f1000research.19149.2. eCollection 2019.
We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy. The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. We decided to initiate treatment with epidermal growth factor receptor (EGFR) inhibitor cetuximab and we reassessed the patient after 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. Cetuximab, like all current treatments for advanced cSCC, is administered off-label and proved effective in preventing further progression of disease in our patient.
我们报告一例60岁男性患者，其胸骨区域患有不可切除的皮肤鳞状细胞癌（cSCC），且不适合放疗。该患者的治疗史值得关注，因为疾病已进展至文献中确立的所有传统治疗方案均无效。我们决定开始使用表皮生长因子受体（EGFR）抑制剂西妥昔单抗进行治疗，并在12周后通过全身CT扫描对患者进行重新评估，结果显示疾病的大小和影像学特征保持稳定。与目前所有用于晚期cSCC的治疗方法一样，西妥昔单抗是在标签外使用的，并且在我们的患者中证明对预防疾病的进一步进展有效。
